Remarkable Boron Delivery Of iRGD-Modified Polymeric Nanoparticles For Boron Neutron Capture Therapy

References

• Barth RF, Zhang Z, Liu T. A realistic appraisal of boron neutron capture therapy as a cancer treatment modality. Cancer Commun (Lond). 2018;38(1):36. doi:10.1186/s40880-018-0280-529914575
   PubMed Web of Science ®Google Scholar
• Barth RF, Mi P, Yang W. Boron delivery agents for neutron capture therapy of cancer. Cancer Commun (Lond). 2018;38(1):35. doi:10.1186/s40880-018-0299-729914561
   PubMed Web of Science ®Google Scholar
• Barth RF, Soloway AH, Fairchild RG, Brugger RM. Boron neutron capture therapy for cancer. Realities and prospects. Cancer. 1992;70(12):2995–3007. doi:10.1002/1097-0142(19921215)70:12<2995::aid-cncr2820701243>3.0.co;2-#1451084
   PubMedGoogle Scholar
• Kreiner AJ, Baldo M, Bergueiro JR, et al. Accelerator-based BNCT. Appl Radiat Isot. 2014;88:185–189. doi:10.1016/j.apradiso.2013.11.06424365468
   PubMedGoogle Scholar
• Kreiner AJ, Bergueiro J, Cartelli D, et al. Present status of accelerator-based BNCT. Rep Pract Oncol Radiother. 2016;21(2):95–101. doi:10.1016/j.rpor.2014.11.00426933390
   PubMedGoogle Scholar
• Michiue H, Sakurai Y, Kondo N, et al. The acceleration of boron neutron capture therapy using multi-linked mercaptoundecahydrododecaborate (BSH) fused cell-penetrating peptide. Biomaterials. 2014;35(10):3396–3405. doi:10.1016/j.biomaterials.2013.12.05524452095
   PubMed Web of Science ®Google Scholar
• Wang J, Wu W, Jiang X. Nanoscaled boron-containing delivery systems and therapeutic agents for cancer treatment. Nanomedicine (Lond). 2015;10(7):1149–1163. doi:10.2217/nnm.14.21325929571
   PubMed Web of Science ®Google Scholar
• Golombek SK, May JN, Theek B, et al. Tumor targeting via EPR: strategies to enhance patient responses. Adv Drug Deliv Rev. 2018;130:17–38. doi:10.1016/j.addr.2018.07.00730009886
   PubMed Web of Science ®Google Scholar
• Hoffman AS. The origins and evolution of “controlled” drug delivery systems. J Control Release. 2008;132(3):153–163. doi:10.1016/j.jconrel.2008.08.01218817820
   PubMed Web of Science ®Google Scholar
• Meo CD, Panza L, Capitani D, et al. Hyaluronan as carrier of carboranes for tumor targeting in boron neutron capture therapy. Biomacromolecules. 2007;8(2):552–559. doi:10.1021/bm060742617291079
   PubMedGoogle Scholar
• Liko F, Hindre F, Fernandez-Megia E. Dendrimers as innovative radiopharmaceuticals in cancer radionanotherapy. Biomacromolecules. 2016;17(10):3103–3114. doi:10.1021/acs.biomac.6b0092927608327
   PubMed Web of Science ®Google Scholar
• Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2010;148(2):135–146. doi:10.1016/j.jconrel.2010.08.02720797419
   PubMed Web of Science ®Google Scholar
• Sugahara KN, Teesalu T, Karmali PP, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science. 2010;328(5981):1031–1035. doi:10.1126/science.118305720378772
   PubMed Web of Science ®Google Scholar
• Curran WJ Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452–1460. doi:10.1093/jnci/djr32521903745
   PubMedGoogle Scholar
• Lawrence TS, Haffty BG, Harris JR. Milestones in the use of combined-modality radiation therapy and chemotherapy. J Clin Oncol. 2014;32(12):1173–1179. doi:10.1200/JCO.2014.55.228124663053
   PubMedGoogle Scholar
• Xu J, Zhang BC, Li XL, et al. Chemosensitization and radiosensitization of a lung cancer cell line A549 induced by a composite polymer micelle. Discov Med. 2016;22(119):7–17.27585226
   PubMed Web of Science ®Google Scholar
• Xu W, Han M, Diao Y, et al. Doxorubicin encapsulated in micelles enhances radiosensitivity in doxorubicin-resistant tumor cells. Discov Med. 2014;18(99):169–177.25336030
   PubMed Web of Science ®Google Scholar
• Xiong XB, Mahmud A, Uludag H, Lavasanifar A. Multifunctional polymeric micelles for enhanced intracellular delivery of doxorubicin to metastatic cancer cells. Pharm Res. 2008;25(11):2555–2566. doi:10.1007/s11095-008-9673-518636321
   PubMed Web of Science ®Google Scholar
• Qi R, Gao Y, Tang Y, et al. PEG-conjugated PAMAM dendrimers mediate efficient intramuscular gene expression. Aaps J. 2009;11(3):395–405. doi:10.1208/s12248-009-9116-119479387
   PubMed Web of Science ®Google Scholar
• Liu HN, Guo NN, Wang TT, et al. Mitochondrial targeted doxorubicin-triphenylphosphonium delivered by hyaluronic acid modified and pH responsive nanocarriers to breast tumor: in vitro and in vivo studies. Mol Pharm. 2018;15(3):882–891. doi:10.1021/acs.molpharmaceut.7b0079329357260
   PubMed Web of Science ®Google Scholar
• Han HD, Lee A, Hwang T, et al. Enhanced circulation time and antitumor activity of doxorubicin by comblike polymer-incorporated liposomes. J Control Release. 2007;120(3):161–168. doi:10.1016/j.jconrel.2007.03.02017524514
   PubMed Web of Science ®Google Scholar
• Xiong H, Zhou D, Qi Y, et al. Doxorubicin-loaded carborane-conjugated polymeric nanoparticles as delivery system for combination cancer therapy. Biomacromolecules. 2015;16(12):3980–3988. doi:10.1021/acs.biomac.5b0131126564472
   PubMed Web of Science ®Google Scholar
• Xu Y, Li Q, Li XY, Yang QY, Xu WW, Liu GL. Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis. J Exp Clin Cancer Res. 2012;31:16. doi:10.1186/1756-9966-31-9522357313
   PubMedGoogle Scholar
• Han M, Huang-Fu MY, Guo WW, et al. MMP-2-sensitive HA end-conjugated poly(amidoamine) dendrimers via click reaction to enhance drug penetration into solid tumor. ACS Appl Mater Interfaces. 2017;9(49):42459–42470. doi:10.1021/acsami.7b1009829143522
   PubMed Web of Science ®Google Scholar
• Radomska A, Leszczyszyn J, Radomski MW, Nanopharmacology T. Nanotoxicology of nanomaterials: new opportunities and challenges. Adv Clin Exp Med. 2016;25(1):151–162. doi:10.17219/acem/6087926935510
   PubMedGoogle Scholar
• Gidwani B, Vyas A. The potentials of nanotechnology-based drug delivery system for treatment of ovarian cancer. Artif Cells Nanomed Biotechnol. 2015;43(4):291–297. doi:10.3109/21691401.2013.85317924245788
   PubMed Web of Science ®Google Scholar
• Zaleskis G, Berleth E, Verstovsek S, Ehrke MJ, Mihich E. Doxorubicin-induced DNA degradation in murine thymocytes. Mol Pharmacol. 1994;46(5):901–908.7969078
   PubMed Web of Science ®Google Scholar
• Xiong XB, Lavasanifar A. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. ACS Nano. 2011;5(6):5202–5213. doi:10.1021/nn201370721627074
   PubMed Web of Science ®Google Scholar
• Pan L, Liu J, Shi J. Cancer cell nucleus-targeting nanocomposites for advanced tumor therapeutics. Chem Soc Rev. 2018;47(18):6930–6946. doi:10.1039/c8cs00081f30062349
   PubMed Web of Science ®Google Scholar
• Shi Y, Li J, Zhang Z, et al. Tracing boron with fluorescence and PET imaging of boronated porphyrin nanocomplex for imaging guided boron neutron capture therapy. ACS Appl Mater Interfaces. 2018;10(50):43387–43395. doi:10.1021/acsami.8b1468230451482
   PubMedGoogle Scholar
• Okumura K, Kinashi Y, Kubota Y, et al. Relative biological effects of neutron mixed-beam irradiation for boron neutron capture therapy on cell survival and DNA double-strand breaks in cultured mammalian cells. J Radiat Res. 2013;54(1):70–75. doi:10.1093/jrr/rrs07922966174
   PubMed Web of Science ®Google Scholar
• Hartman T, Carlsson J. Radiation dose heterogeneity in receptor and antigen mediated boron neutron capture therapy. Radiother Oncol. 1994;31(1):61–75. doi:10.1016/0167-8140(94)90414-68041899
   PubMedGoogle Scholar
• Barth RF, Coderre JA, Vicente MG, Blue TE. Boron neutron capture therapy of cancer: current status and future prospects. Clin Cancer Res. 2005;11(11):3987–4002. doi:10.1158/1078-0432.CCR-05-003515930333
   PubMed Web of Science ®Google Scholar
• Soloway AH, Hatanaka H, Davis MA. Penetration of brain and brain tumor. VII. Tumor-binding sulfhydryl boron compounds. J Med Chem. 1967;10(4):714–717. doi:10.1021/jm00316a0426037065
   PubMed Web of Science ®Google Scholar
• Wada Y, Hirose K, Harada T, et al. Impact of oxygen status on 10B-BPA uptake into human glioblastoma cells, referring to significance in boron neutron capture therapy. J Radiat Res. 2018;59(2):122–128. doi:10.1093/jrr/rrx08029315429
   PubMed Web of Science ®Google Scholar
• Alberti D, Deagostino A, Toppino A, et al. An innovative therapeutic approach for malignant mesothelioma treatment based on the use of Gd/boron multimodal probes for MRI guided BNCT. J Control Release. 2018;280:31–38. doi:10.1016/j.jconrel.2018.04.04329730155
   PubMedGoogle Scholar
• Gao Z, Horiguchi Y, Nakai K, et al. Use of boron cluster-containing redox nanoparticles with ROS scavenging ability in boron neutron capture therapy to achieve high therapeutic efficiency and low adverse effects. Biomaterials. 2016;104:201–212. doi:10.1016/j.biomaterials.2016.06.04627467416
   PubMed Web of Science ®Google Scholar
• Feng B, Tomizawa K, Michiue H, et al. Delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-His. Biomaterials. 2009;30(9):1746–1755. doi:10.1016/j.biomaterials.2008.12.01019121537
   PubMed Web of Science ®Google Scholar
• Miyata S, Kawabata S, Hiramatsu R, et al. Computed tomography imaging of transferrin targeting liposomes encapsulating both boron and iodine contrast agents by convection-enhanced delivery to F98 rat glioma for boron neutron capture therapy. Neurosurgery. 2011;68(5):1380–1387. discussion 1387. doi:10.1227/NEU.0b013e31820b52aa21273928
   PubMed Web of Science ®Google Scholar
• Nieberler M, Reuning U, Reichart F, et al. Exploring the role of RGD-recognizing integrins in cancer. Cancers (Basel). 2017;9(9):116. doi:10.3390/cancers9090116
   PubMed Web of Science ®Google Scholar
• Burazin A, Drapaca CS, Tenti G, Sivaloganathan S. A poroelasticity theory approach to study the mechanisms leading to elevated interstitial fluid pressure in solid tumours. Bull Math Biol. 2018;80(5):1172–1194. doi:10.1007/s11538-017-0383-129282596
   PubMedGoogle Scholar
• Seymour LW, Ulbrich K, Steyger PS, et al. Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br J Cancer. 1994;70(4):636–641. doi:10.1038/bjc.1994.3637917909
   PubMedGoogle Scholar
• Walker-Samuel S, Roberts TA, Ramasawmy R, et al. Investigating low-velocity fluid flow in tumors with convection-MRI. Cancer Res. 2018;78(7):1859–1872. doi:10.1158/0008-5472.CAN-17-154629317434
   PubMedGoogle Scholar
• Ma CH, Jiang R, Li JD, Wang B, Sun LW, Lv Y. Experimental study of endostar injection concomitant with cryoablation on lung adenocarcinoma A549 xenografts. Asian Pac J Cancer Prev. 2014;14(11):6697–6701. doi:10.7314/apjcp.2013.14.11.669724377591
   PubMedGoogle Scholar
• Xu Q, Gu J, Lv Y, et al. Angiogenesis for tumor vascular normalization of endostar on hepatoma 22 tumor-bearing mice is involved in the immune response. Oncol Lett. 2018;15(3):3437–3446. doi:10.3892/ol.2018.773429467868
   PubMedGoogle Scholar